

Prescription Pharmaceutical Products¹

PRODUCT*	INDICATION	TERRITORY					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
Oncology/Hematology							
Minjuvi®	Autologous stem cell transplant (ASCT) ineligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)		Q1-24	Q4-25		Q1-25	Incyte
Minjuvi®	Relapsed or refractory follicular lymphoma (FL)		●	▲	▲	▲	Incyte
Pemazyre®	Unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion		Q4-25	●		Q4-25	Incyte
Akynzeo®	Prevention of chemotherapy-induced acute and delayed nausea and vomiting	Q4-22	Q3-22	Q3-22			Helsinn
Aloxi® / Onicit®	Prevention of acute nausea and vomiting associated with moderate and highly emetogenic cancer chemotherapy	Q4-22	Q1-25			Q1-25	Helsinn
Tavalisse®	Previously treated chronic immune thrombocytopenia		●	●	●	■	Rigel
Trelstar®	Advanced prostate cancer	Q2-20					Debiopharm
Vidaza®	Myelodysplastic syndrome		Q2-10				BMS
Abraxane®	Metastatic adenocarcinoma of the pancreas		Q4-17				BMS
Halaven®	Metastatic breast cancer and liposarcoma subtype of soft tissue sarcoma		Q4-17	Q4-19	Q2-22		Eisai
Lenvima®	Locally advanced or metastatic differentiated thyroid cancer and previously untreated advanced or unresectable hepatocellular carcinoma		Q4-17		Q1-22		Eisai
Lenvima®	Advanced renal cell cancer		Q4-17				Eisai
Orgovyx®	Advanced prostate cancer	Q1-24					Sumitomo
BGx							
Ladevina® (lenalidomide)	Multiple myeloma; myelodysplastic syndrome			2011	Q3-19		Own
Ladevina® (lenalidomide)	Mantle Cell Lymphoma; previously treated follicular lymphoma			2011			Own
Zyvalix® (abiraterone)	Metastatic castration-resistant prostate cancer			2014	Q2-18		Own
Karfib® (carfilzomib)	Relapsed or refractory multiple myeloma			Q4-19	■		Own
Leprid® (leuprolide)	Palliative treatment of advanced prostate cancer			2007			Own
Rembre® (dasatinib)	Philadelphia chromosome-positive chronic myeloid leukemia			2013	Q1-22		Own
Palbocil®, Bapocil® (palbociclib)	Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer			Q1-23	●		Own
Xetrane® (pomalidomide)	Multiple myeloma			Q2-19	●		Own
Xetrane® (pomalidomide)	AIDS-related Kaposi sarcoma			Q2-22			Own

¹ See MD&A for more details.

▲ Pre-registration: Not yet submitted for regulatory review. The indication is the anticipated indication upon regulatory approval.

● Submitted: Currently under regulatory review. The indication is the anticipated indication upon regulatory approval.

■ Approved: Approved by regulatory authorities but not yet commercially launched.

*The trademarks and logos of in-licensed products are typically owned by the respective partners. For example: MINJUVI, PEMAZYRE, ZYNYZ and NIKTIMVO, and their respective logos, are registered trademarks or trademarks of Incyte.



Prescription Pharmaceutical Products¹

PRODUCT*	INDICATION	TERRITORY					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
Infectious Diseases							
Ambisome®	Invasive fungal infection		1997				Gilead
Cresemba®	Invasive fungal infection		Q2-20	Q3-19	Q3-19	Q2-19	Basilea
Impavido®	Leishmaniasis						Own
BGx							
Dolufevir® (dolutegravir)	HIV infection			Q2-21			Own
Other Specialty							
Exelon®	Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease	Q2-21	Q2-21	Q2-21	Q2-21	Q2-21	Own
Ibsrela®	Irritable bowel syndrome with constipation (IBS-C)	Q1-21					Ardelyx
Salofalk®	Acute ulcerative colitis			2007	Pre-2019		Dr. Falk
Ursofalk®	Primary biliary cirrhosis			2007	Pre-2019		Dr. Falk
Imvexxy®	Moderate-to-severe dyspareunia	Q1-24					TXMD
Bijuva®	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24					TXMD
Dexedrine®	Attention-Deficit Hyperactivity Disorder (ADHD)	1940's					Own
Testim®	Testosterone deficiency	2007					Endo
Envarsus®PA	Prophylaxis of organ rejection in allogenic kidney or liver transplant in combination with other immunosuppressants	Q2-19					Veloxis
Xcopri®	Adjunctive therapy in the management of partial-onset seizures in adults with epilepsy	Q1-24					SK
Myfembree®	Treatment for heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis in pre-menopausal women	Q1-24					Sumitomo
BGx							
Fibridoner® (pirfenidone)	Idiopathic pulmonary fibrosis			2017			Own

¹ See MD&A for more details.

*The trademarks and logos of in-licensed products are typically owned by the respective partners. For example: MINJUVI, PEMAZYRE, ZYNYZ and NIKTIMVO, and their respective logos, are registered trademarks or trademarks of Incyte.



Pipeline and Products in Early Launch Stage¹

PRODUCT*	INDICATION OR THERAPEUTIC AREA	TERRITORY					EXPECTED LAUNCH YEAR
		Canada	Brazil	Argentina	Colombia	Mexico	
Oncology/Hematology							
Minjuvi®	Autologous stem cell transplant (ASCT) ineligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)		Q1-24	Q4-25		Q1-25	2025-2026
Minjuvi®	Relapsed or refractory follicular lymphoma (FL)		●	▲	▲	▲	2027
Retifanlimab	Squamous cell carcinoma of the anal canal Advanced Merkel cell carcinoma		▲	▲	▲	▲	2027-2029
Axatilimab	Chronic graft-versus-host disease		▲	▲		▲	2027-2029
Pemazyre®	Unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion		Q4-25	■		Q4-25	2025-2026
Tavalisse®	Previously treated of chronic immune thrombocytopenia		●	●	●	■	2026-2027
Bapocil®	Breast Cancer				●		2026
Xetrane®	Multiple myeloma			Q2-19	●		2029
Rembre®	Philadelphia chromosome-positive chronic myeloid leukemia				Q1-22		—
O501	Oncology/Hematology			■			2025
O502	Oncology/Hematology			■			2025
O503	Oncology/Hematology			▲			2027
O401	Oncology/Hematology		◆				2027-2028
O402	Oncology/Hematology		◆				2027-2028
H403	Oncology/Hematology		◆		◆		2027-2028
H402	Oncology/Hematology		◆		◆		2028-2029
Other Specialty							
Imvexxy®	Moderate-to-severe dyspareunia	Q1-24					—
Bijuva®	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24					—
Crexont®	Parkinson’s disease	●	▲	▲	▲	●	2027-2028
Qelbree®	Attention-Deficit Hyperactivity Disorder (ADHD)	●					2027
Jornay PM™	Attention-Deficit Hyperactivity Disorder (ADHD)	Q4-25	▲			▲	2025-2028
Xcopri®	Adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy	Q1-24					—
Myfembree®	Treatment for heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis in pre-menopausal women	Q1-24					—
Orgovyx®	Advanced prostate cancer	Q1-24					—
Wynzora®	Plaque psoriasis	●					2026-2027
Vibegron	Treatment of overactive bladder, or OAB	▲					2028
C401 (Neurology)	Other Specialty				■		2026

¹ See MD&A for more details.

◆ Development: Products under development stage.

▲ Pre-registration: Not yet submitted for regulatory review. The indication is the anticipated indication upon regulatory approval.

● Submitted: Currently under regulatory review. The indication is the anticipated indication upon regulatory approval.

■ Approved: Approved by regulatory authorities but not yet commercially launched.

*The trademarks and logos of in-licensed products are typically owned by the respective partners. For example: MINJUVI, PEMAZYRE, ZYNYZ and NIKTIMVO, and their respective logos, are registered trademarks or trademarks of Incyte.